¼¼°èÀÇ CRISPR ±â¹Ý Áø´Ü ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : Á¦Ç°º°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2030³â)
CRISPR-Based Diagnostics Market Size, Share & Trends Analysis Report By Product (Enzymes, Kits & Reagents, Software & Libraries), By Technology (Cas9, Cas12), By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå
:
1750865
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2025³â 05¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 100 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼¼°èÀÇ CRISPR ±â¹Ý Áø´Ü ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ
Grand View Research, IncÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é ¼¼°èÀÇ CRISPR ±â¹Ý Áø´Ü ½ÃÀå ±Ô¸ð´Â 2025-2030³â±îÁö 16.57%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ±â·ÏÇØ 2030³â 75¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. »õ·Î¿î Cas È¿¼ÒÀÇ °³¹ßÀº CRISPR ±â¹Ý Áø´Ü °Ë»çÀÇ ¹Î°¨µµ¿Í ƯÀ̼ºÀ» Çâ»ó ½ÃÄ×½À´Ï´Ù. ÀÌ·¯ÇÑ Áøº¸·Î º´¿øÃ¼¿Í À¯ÀüÀÚ µ¹¿¬º¯À̸¦ ³ôÀº Á¤È®µµ·Î °¨Áö ÇÒ ¼öÀÖ´Â ½Å¼ÓÇÑ Æ÷ÀÎÆ® ¿Àºê Äɾî(POC) Áø´Ü µµ±¸ÀÇ °³¹ßÀÌ ÃËÁøµÇ¾ú½À´Ï´Ù.
½ÃÀå ±Ô¸ðÀÇ ±ÞÁõÀº ÇコÄɾî ÁöÃâ Áõ°¡, À¯ÀüÀÚ ÆíÁý ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¸¸¼º ÁúȯÀ̳ª À¯Àü¼º ÁúȯÀÇ ¸¸¿¬ µîÀÇ ¿äÀο¡ ÀÇÇÑ °ÍÀÔ´Ï´Ù. °áÇÙÀº ¿©ÀüÀÌ ¼¼°è¿¡¼ 2¹øÂ°·Î ¸¹Àº °¨¿°ÁõÀ̸ç, 2023³â¿¡´Â ÃßÁ¤ 1,080¸¸¸íÀÌ °áÇÙÀ¸·Î Áø´ÜµÇ¾ú´Ù°í º¸°íÇϰí ÀÖ½À´Ï´Ù.
À¯Àü¼º Áúȯ°ú Àü¿°º´ÀÇ ¼¼°è¿¡ ÀÖ´Â ÀÌȯÀ² Áõ°¡´Â Áøº¸µÈ Áø´Ü °ø±¸¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁõÆø½Ã۰í ÀÖ½À´Ï´Ù. ±¹Á¦¾Ï ¿¬±¸±â°ü¿¡ µû¸£¸é ¼¼°èÀÇ ½Å±Ô¾Ï ȯÀÚ¼ö´Â 2025³â 2,130¸¸¸í¿¡¼ 2050³â 3,530¸¸¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. À¯»çÇϰÔ, 2024³â 8¿ù¿¡ Lancet ÀâÁö¿¡ °ÔÀçµÈ ¿¬±¸´Â ºñÀ¯·´°è ÁÖ¹Î, ƯÈ÷ Àεµ ¾Æ´ë·ú¿¡¼ ³¶Æ÷¼º ¼¶À¯ÁõÀÇ À¯º´·üÀÌ ¿¹»óº¸´Ù ³ô´Ù´Â °ÍÀ» ¹àÇû½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀº CRISPR ±â¹Ý °Ë»ç¿Í °°Àº ´Ù¾çÇÑ Áúº´ÀÇ Á¶±â ¹ß°ß ¹× Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â Á¤¹ÐÇÏ°í ½Å¼ÓÇÑ Áø´Ü ¹æ¹ýÀÇ Çʿ伺À» °Á¶ÇÕ´Ï´Ù. ƯÁ¤ À¯ÀüÀÚ ¼¿À» Á¤È®ÇÏ°Ô È®ÀÎÇÏ´Â CRISPR Áø´ÜÀÇ ´É·ÂÀº À¯Àü¼º Áúȯ°ú °¨¿°À¸·Î ÀÎÇÑ ºÎ´ã Áõ°¡¿¡ ´ëóÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.
Áö¿ªÀûÀ¸·Î CRISPR ±â¹Ý Áø´Ü ½ÃÀåÀº ´Ù¾çÇÑ ¼ºÀå ÆÐÅÏÀ» º¸¿©ÁÝ´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÇöÀç °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí Àִµ¥, ÀÌ´Â Àü¿°º´ÀÇ À¯Çà°ú °Ç° °ü¸® ÀÎÇÁ¶ó ÅõÀÚ Áõ°¡·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù. ÇÑÆí, ºÏ¹Ì´Â R&D ÅõÀÚÀÇ Ãæ½Ç°ú ÷´Ü Áø´Ü ±â¼úÀÇ Á¶±â µµÀÔÀ¸·Î °¡Àå ±Þ¼ºÀåÇÏ´Â Áö¿ªÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 9¿ù, Sherlock Biosciences´Â ÀÎÀ¯µÎÁ¾ ¹ÙÀÌ·¯½º(HPV) °ËÃâÀ» À§ÇÑ CRISPR ±â¼úÀ» Ȱ¿ëÇÑ ½Å¼ÓÇÏ°í ±â±¸°¡ ÇÊ¿ä ¾ø´Â ºÐÀÚÁø´Ü¹ýÀÇ °³¹ßÀ» °ÈÇϱâ À§ÇØ Bill & Melinda Gates FoundationÀ¸·ÎºÎÅÍ Ãß°¡ ÀÚ±ÝÀ» ¹Þ¾Ò½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÌ´Ï¼ÅÆ¼ºê´Â °øÁß º¸°Ç ¹®Á¦ ÇØ°á¿¡ CRISPR ±â¼úÀ» Ȱ¿ëÇÏ·Á´Â Áö¿ªÀÇ ³ë·ÂÀ» ¹Ý¿µÇÕ´Ï´Ù.
CRISPR ±â¹Ý Áø´Ü ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- 2024³â, Á¦Ç°º°·Î´Â ŰƮ ¹× ½Ã¾àÀÌ ÃÖ´ëÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» °ßÀÎÇßÀ¸¸ç, CRISPR ±â¹ÝÀÇ °ËÃ⠽ýºÅÛÀÌ ÀÓ»ó°ú ¿¬±¸ÀÇ ¾çÂÊ ¸ðµÎ¿¡¼ ³Î¸® Àü°³µÇ°í ÀÖ´Â °ÍÀÌ ±× ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.
- ±â¼úº°·Î´Â Cas9°¡ CRISPR ±â¼ú °³¹ß¿¡ ÀÖ¾î¼ÀÇ ±âº»ÀûÀÎ ¿ªÇÒ¿¡ ÀÇÇØ 2024³â¿¡ ¾ÐµµÀûÀÎ ½ÃÀå Á¡À¯À²À» È®º¸Çß½À´Ï´Ù.
- ¿ëµµº°·Î´Â °¨¿°Áõ Áø´ÜÀÌ 2024³â¿¡ ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, À̰ÍÀº ½Å¼ÓÇϰí Á¤È®Çϰí È®Àå °¡´ÉÇÑ °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼¼°èÀÇ ±ä±Þ ¿ä±¸¿¡ ÀÇÇÑ °ÍÀÔ´Ï´Ù.
- HIV, °£¿°, °áÇÙ, È£Èí±â °¨¿°Áõ µî, Á¤È®ÇÏ°í ½Ã±â ÀûÀýÇÑ Áø´ÜÀ» ÇÊ¿ä·Î ÇÏ´Â °¨¿°ÁõÀÇ À¯ÇàÀÌ ³ô¾ÆÁö°í ÀÖ´Â °ÍÀÌ ¹è°æ¿¡ ÀÖ½À´Ï´Ù.
- ºÏ¹Ì´Â ¸¸¼ºÁúȯÀ̳ª °¨¿°ÁõÀÇ ÀÌȯÀ²ÀÌ ³ôÀº °Í, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ´Â °Í, ¿¬±¸°³¹ß ÁöÃâÀÌ ¸¹Àº °Í, Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î °Ë»ç°¡ ÁøÇàµÇ°í ÀÖ´Â °Í µîÀÌ ¿äÀÎÀÌ µÇ¾î, 2024³â ¼¼°è ½ÃÀå¿¡¼ ÃÖ´ëÀÇ ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå CRISPR ±â¹Ý Áø´Ü ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå ¼Ò°³/°èÅë Àü¸Á
- ½ÃÀå ±Ô¸ð¿Í ¼ºÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- CRISPR ±â¹Ý Áø´Ü ½ÃÀå ºÐ¼® µµ±¸
- Porter's Five Forces ºÐ¼®
- PESTEL ºÐ¼®
Á¦4Àå CRISPR ±â¹Ý Áø´Ü ½ÃÀå : Á¦Ç°º°, ÃßÁ¤ ¹× µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- CRISPR ±â¹Ý Áø´Ü ½ÃÀå : Á¦Ç° º¯µ¿ ºÐ¼®, 2024³â ¹× 2030³â
- È¿¼Ò
- ŰƮ ¹× ½Ã¾à
- ¼ÒÇÁÆ®¿þ¾î ¹× ¶óÀ̺귯¸®
Á¦5Àå CRISPR ±â¹Ý Áø´Ü ½ÃÀå : ±â¼úº°, ÃßÁ¤ ¹× µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- CRISPR ±â¹Ý Áø´Ü ½ÃÀå : ±â¼ú º¯µ¿ ºÐ¼®, 2024³â ¹× 2030³â
- Cas9
- Cas12
- ±âŸ
Á¦6Àå CRISPR ±â¹Ý Áø´Ü ½ÃÀå : ¿ëµµº°, ÃßÁ¤ ¹× µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- CRISPR ±â¹Ý Áø´Ü ½ÃÀå : ¿ëµµ º¯µ¿ ºÐ¼®, 2024³â ¹× 2030³â
- °¨¿°Áõ Áø´Ü
- À¯Àü¼º Áúȯ Áø´Ü
- ¾Ï Áø´Ü
- ±âŸ
Á¦7Àå CRISPR ±â¹Ý Áø´Ü ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, ÃßÁ¤ ¹× µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- CRISPR ±â¹Ý Áø´Ü ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®, 2024³â ¹× 2030³â
- º´¿ø ¹× Áø·á¼Ò Áø´Ü
- ¿¬±¸¼Ò
- Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
- ±âŸ
Á¦8Àå CRISPR ±â¹Ý Áø´Ü ½ÃÀå : Áö¿ªº°, ÃßÁ¤ ¹× µ¿Ç⠺м®
- CRISPR ±â¹Ý Áø´Ü ½ÃÀå Á¡À¯À²: Áö¿ªº°, 2024³â ¹× 2030³â
- ºÏ¹Ì
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- µ§¸¶Å©
- ½º¿þµ§
- ³ë¸£¿þÀÌ
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- È£ÁÖ
- Çѱ¹
- ű¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- Äí¿þÀÌÆ®
Á¦9Àå °æÀï ±¸µµ
- ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷¿¡ ÀÇÇÑ ÃÖ±ÙÀÇ µ¿Çâ°ú ¿µÇ⠺м®
- ±â¾÷ ºÐ·ù
- ±â¾÷ È÷Æ®¸Ê ºÐ¼®
- ±â¾÷ ÇÁ·ÎÆÄÀÏ
- Thermo Fisher Scientific Inc.
- Integrated DNA Technologies, Inc.
- Molbio Diagnostics
- Horizon Discovery
- Synthego Corporation
- Mammoth Biosciences
- Sherlock Biosciences
- Caribou Biosciences
- CrisprBits
- ToolGen Inc.
>JHS
¿µ¹® ¸ñÂ÷
CRISPR-based Diagnostics Market Growth & Trends:
The global CRISPR-based diagnostics market size is expected to reach USD 7.55 billion by 2030, registering a CAGR of 16.57% from 2025 to 2030, according to a new report by Grand View Research, Inc. Technological innovations have been pivotal in propelling the CRISPR diagnostics market forward. The development of novel Cas enzymes, such as Cas12 and Cas13, has enhanced the sensitivity and specificity of CRISPR-based diagnostic tests. These advancements have facilitated the creation of rapid, point-of-care (POC) diagnostic tools capable of detecting pathogens and genetic mutations with high accuracy. In August 2023, Indian biotech startup CrisprBits collaborated with Molbio Diagnostics to develop CRISPR-based POC tests. This partnership led to the creation of the PathCrisp platform, designed for rapid and precise disease detection, and has been instrumental in expanding the availability of CRISPR diagnostics in resource-limited settings. Such collaborations exemplify how technological advancements are translating into practical diagnostic solutions.
The surge in market size is attributed to factors such as increased healthcare spending, heightened demand for gene editing technologies, and a growing prevalence of chronic and genetic diseases. For instance, the World Health Organization reported in 2024 that tuberculosis (TB) remained the second most common infectious disease worldwide, with an estimated 10.8 million people diagnosed in 2023 Such statistics underscore the pressing need for advanced diagnostic tools such as CRISPR-based tests.
The increasing incidence of genetic disorders and infectious diseases globally has amplified the demand for advanced diagnostic tools. According to the International Agency for Research on Cancer, the number of new cancer cases worldwide is expected to rise from 21.3 million in 2025 to 35.3 million by 2050. Similarly, research published in The Lancet in August 2024 highlighted a higher-than-expected prevalence of cystic fibrosis in non-European populations, particularly in the Indian subcontinent. These trends underscore the necessity for precise and rapid diagnostic methods, such as CRISPR-based tests, which can facilitate early detection and treatment of various diseases. The ability of CRISPR diagnostics to accurately identify specific genetic sequences makes them invaluable in managing the growing burden of genetic and infectious diseases.
Geographically, the CRISPR diagnostics market exhibits varying growth patterns. Asia Pacific currently holds the largest market share, driven by a high prevalence of infectious diseases and increasing investments in healthcare infrastructure. Conversely, North America is projected to be the fastest-growing region, attributed to substantial research and development investments and early adoption of advanced diagnostic technologies. For instance, in September 2023, Sherlock Biosciences received additional funding from the Bill & Melinda Gates Foundation to enhance the development of rapid, instrument-free molecular diagnostics leveraging CRISPR technology for Human Papillomavirus (HPV) detection . Such initiatives reflect the regional efforts to harness CRISPR technology in addressing public health challenges.
CRISPR-based Diagnostics Market Report Highlights:
- In 2024, kits and reagents led the market with a largest revenue share, driven by the widespread deployment of CRISPR-based detection systems in both clinical and research settings. The increasing global demand for point-of-care diagnostics, particularly for infectious and genetic diseases, has amplified the need for ready-to-use diagnostic kits and high-quality reagents.
- The Cas9 segment secured the dominant market share in 2024, due to its foundational role in the development of CRISPR technologies. As the first and most widely studied CRISPR-associated protein, Cas9 has been instrumental in enabling precise DNA targeting and cleavage, making it a preferred tool for genetic diagnostics
- The infectious disease diagnostics held the largest market share in 2024, driven by the urgent global need for rapid, accurate, and scalable testing solutions. CRISPR technologies, particularly those leveraging Cas12 and Cas13, enable highly sensitive detection of viral and bacterial pathogens by identifying nucleic acid sequences with precision.
- Pharmaceutical and biotechnology companies held the dominant market share in 2024 and is expected to be the fastest-growing segment over the forecast period. driven by the rising prevalence of infectious diseases such as HIV, hepatitis, tuberculosis, and respiratory infections, which require accurate and timely diagnosis.
- North America dominated the global market with the largest revenue share in 2024, driven by a high burden of chronic and infectious diseases, a growing focus on personalized medicine, substantial R&D spending, and advances in point-of-care testing.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. CRISPR-Based Diagnostics Market Variables, Trends, & Scope
- 3.1. Market Introduction/Lineage Outlook
- 3.2. Market Size and Growth Prospects (USD Million)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
- 3.4. CRISPR-Based Diagnostics Market Analysis Tools
- 3.4.1. Porter's Analysis
- 3.4.1.1. Bargaining power of the suppliers
- 3.4.1.2. Bargaining power of the buyers
- 3.4.1.3. Threats of substitution
- 3.4.1.4. Threats from new entrants
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Economic and Social landscape
- 3.4.2.3. Technological landscape
- 3.4.2.4. Environmental landscape
- 3.4.2.5. Legal landscape
Chapter 4. CRISPR-Based Diagnostics Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. CRISPR-Based Diagnostics Market: Product Movement Analysis, 2024 & 2030 (USD Million)
- 4.3. Enzymes
- 4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4. Kits and Reagents
- 4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.5. Software and Libraries
- 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. CRISPR-Based Diagnostics Market: Technology Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. CRISPR-Based Diagnostics Market: Technology Movement Analysis, USD Million, 2024 & 2030
- 5.3. Cas9
- 5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4. Cas12
- 5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5. Others
- 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. CRISPR-Based Diagnostics Market: Application Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. CRISPR-Based Diagnostics Market: Application Movement Analysis, USD Million, 2024 & 2030
- 6.3. Infectious Disease Diagnostics
- 6.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4. Genetic Disorder Diagnostics
- 6.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5. Cancer Diagnostics
- 6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6. Others
- 6.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. CRISPR-Based Diagnostics Market: End Use Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. CRISPR-Based Diagnostics Market: End Use Movement Analysis, USD Million, 2024 & 2030
- 7.3. Hospitals and Clinics Diagnostic
- 7.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4. Laboratories
- 7.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5. Pharmaceutical and Biotechnology Companies
- 7.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6. Others
- 7.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. CRISPR-Based Diagnostics Market: Regional Estimates & Trend Analysis
- 8.1. CRISPR-Based Diagnostics Market Share, By Region, 2024 & 2030 ( USD Million)
- 8.2. North America
- 8.2.1. North America CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.2. U.S.
- 8.2.2.1. U.S. CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.3. Canada
- 8.2.3.1. Canada CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.4. Mexico
- 8.2.4.1. Mexico CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3. Europe
- 8.3.1. Europe CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.2. UK
- 8.3.2.1. UK CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.3. Germany
- 8.3.3.1. Germany CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.4. France
- 8.3.4.1. France CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.5. Italy
- 8.3.5.1. Italy CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.6. Spain
- 8.3.6.1. Spain CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.7. Denmark
- 8.3.7.1. Denmark CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.8. Sweden
- 8.3.8.1. Sweden CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.9. Norway
- 8.3.9.1. Norway CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4. Asia Pacific
- 8.4.1. Asia Pacific CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.2. Japan
- 8.4.2.1. Japan CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.3. China
- 8.4.3.1. China CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.4. India
- 8.4.4.1. India CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.5. Australia
- 8.4.5.1. Australia CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.6. South Korea
- 8.4.6.1. South Korea CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.7. Thailand
- 8.4.7.1. Thailand CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5. Latin America
- 8.5.1. Latin America CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.2. Brazil
- 8.5.2.1. Brazil CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.3. Argentina
- 8.5.3.1. Argentina CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6. Middle East and Africa
- 8.6.1. Middle East and Africa CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.2. South Africa
- 8.6.2.1. South Africa CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.3. Saudi Arabia
- 8.6.3.1. South Africa CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.4. UAE
- 8.6.4.1. UAE CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.5. Kuwait
- 8.6.5.1. Kuwait CRISPR-Based Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Recent Developments & Impact Analysis by Key Market Participants
- 9.2. Company Categorization
- 9.3. Company Heat Map Analysis
- 9.4. Company Profiles
- 9.4.1. Thermo Fisher Scientific Inc.
- 9.4.1.1. Participant's Overview
- 9.4.1.2. Financial Performance
- 9.4.1.3. Product Benchmarking
- 9.4.1.4. Recent Developments/ Strategic Initiatives
- 9.4.2. Integrated DNA Technologies, Inc.
- 9.4.2.1. Participant's Overview
- 9.4.2.2. Financial Performance
- 9.4.2.3. Product Benchmarking
- 9.4.2.4. Recent Developments/ Strategic Initiatives
- 9.4.3. Molbio Diagnostics
- 9.4.3.1. Participant's Overview
- 9.4.3.2. Financial Performance
- 9.4.3.3. Product Benchmarking
- 9.4.3.4. Recent Developments/ Strategic Initiatives
- 9.4.4. Horizon Discovery
- 9.4.4.1. Participant's Overview
- 9.4.4.2. Financial Performance
- 9.4.4.3. Product Benchmarking
- 9.4.4.4. Recent Developments/ Strategic Initiatives
- 9.4.5. Synthego Corporation
- 9.4.5.1. Participant's Overview
- 9.4.5.2. Financial Performance
- 9.4.5.3. Product Benchmarking
- 9.4.5.4. Recent Developments/ Strategic Initiatives
- 9.4.6. Mammoth Biosciences
- 9.4.6.1. Participant's Overview
- 9.4.6.2. Financial Performance
- 9.4.6.3. Product Benchmarking
- 9.4.6.4. Recent Developments/ Strategic Initiatives
- 9.4.7. Sherlock Biosciences
- 9.4.7.1. Participant's Overview
- 9.4.7.2. Financial Performance
- 9.4.7.3. Product Benchmarking
- 9.4.7.4. Recent Developments/ Strategic Initiatives
- 9.4.8. Caribou Biosciences
- 9.4.8.1. Participant's Overview
- 9.4.8.2. Financial Performance
- 9.4.8.3. Product Benchmarking
- 9.4.8.4. Recent Developments/ Strategic Initiatives
- 9.4.9. CrisprBits
- 9.4.9.1. Participant's Overview
- 9.4.9.2. Financial Performance
- 9.4.9.3. Product Benchmarking
- 9.4.9.4. Recent Developments/ Strategic Initiatives
- 9.4.10. ToolGen Inc.
- 9.4.10.1. Participant's Overview
- 9.4.10.2. Financial Performance
- 9.4.10.3. Product Benchmarking
- 9.4.10.4. Recent Developments/ Strategic Initiatives
°ü·ÃÀÚ·á